Merck, AstraZeneca report positive data for Koselugo in adults

AstraZeneca (NASDAQ:AZN) and Merck (NYSE:MRK) reported positive topline results from a Phase 3 study of their drug Koselugo in the treatment of neurofibromatosis type 1, or NF1.